Dhishant Asarpota was appointed to the Wright State University Board of Trustees for a term beginning July 1, 2020, and ending June 30, 2022. He replaced Shaun Wenrick.
Asarpota is an M.D. candidate at Wright State University Boonshoft School of Medicine and is scheduled to graduate in 2022. He has been an active member of the university since enrolling at Boonshoft School of Medicine in 2018. He is president of Business of Medicine, an organization that aims to create more well-rounded physicians with a capacity to understand the inner workings of the health care system. As chair of the Admissions Welcome Committee, Asarpota coordinated the greeting of medical applicants by recruiting passionate medical students to showcase the diversity and capabilities of the School of Medicine. He has also engaged in peer education via tutoring and leading workshops, serves as a trustee on the Wright State Academy of Medicine, volunteers for the Anatomical Gift Program, and participates in academic committees.
In addition, Asarpota prioritizes research alongside his clinical education. He has partnered with Wright State Physicians and the University of Dayton to highlight the gaps in screening practices for complications after breast cancer surgery. He is also studying the collateral impact of COVID-19 on morbidity and mortality. The Academy of Medicine has recognized Asarpota with the Outstanding Medical Student award two years in a row.
Asarpota earned an M.B.A. and a master's degree in medical physiology from Case Western Reserve University and a bachelor's degree in biochemistry and molecular biology from Boston University.
As an undergraduate student at Boston University, Asarpota traveled to Honduras four times to deliver health care to underserved communities through Global Medical Brigades, an organization he led as vice president and regional chair. He was also a resident assistant, student researcher, and emergency medical technician.
After graduate school, Asarpota worked at McKinsey and Company within the pharmaceuticals and medical products practice, where he focused on the commercialization, access, and valuation of therapeutics.
Terms ends 2022.